Chemical treatment of anti-D results in improved efficacy for the inhibition of Fcγ receptor-mediated phagocytosis

Transfusion

Volumn 47, Issue 12, 2007, Pages 2250-2259

  Foo, Alison H ^b   Ramkumar, Stephanie ^b   Helke, Simone ^b   Branch, Donald R ^a  

^a CANADIAN BLOOD SERVICES   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN; RHESUS D ANTIBODY; THIOMERSAL;

ARTICLE; CELL CULTURE; CELL STRAIN THP 1; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; PHAGOCYTOSIS;

CELL LINE; ERYTHROCYTES; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; ISOANTIBODIES; MONOCYTES; PHAGOCYTOSIS; RECEPTORS, IGG; THIMEROSAL;

EID: 36348947389     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01454.x     Document Type: Article

References (37)

1. El-Shanawany T, Sewell WA, Misbah SA, Jolles S. Current clinical uses of intravenous immunoglobulin. Clin Med 2006 6 : 356 9.
2. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006 46 : 741 53.
3. Bussel J. Treatment of immune thrombocytopenic purpura in adults. Semin Hematol 2006 43 (3 Suppl 5 S3 10.
4. Crow AB, Lazarus A. Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003 25 : S14 8.
5. Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 2004 79 : 504 22.
6. Cowden J, Parker SK. Intravenous immunoglobulin: production, uses and side effects. Pediatr Infect Dis J 2006 25 : 641 2.
7. Milgrom H. Shortage of intravenous immunoglobulin. Ann Allergy Asthma Immunol 1998 81 : 97 100.
8. Gaines AR. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 2000 95 : 2523 9.
9. Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005 106 : 1532 7.
10. Sekul E, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994 121 : 259 62.
11. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000 75 : 83 5.
12. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994 44 : 223 6.
13. Elkayam O, Paran D, Milo R, Davidovitz Y, Almoznino-Sarafian D, Zeltser D, Yaron M, Caspi D. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders: a study of four cases. Ann Rheum Dis 2000 59 : 77 80.
14. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986 2 : 217 8.
15. Rampersad G, Suck G, Sakac D, Fahim S, Foo A, Denomme GA, Langler RF, Branch DR. Chemical compounds that target thiol/disulfide groups on mononuclear phagocytes inhibit immune mediated phagocytosis of red blood cells. Transfusion 2005 45 : 384 93.
16. Foo AH, Fletcher SP, Langler RF, Porter CH, Branch DR. Structure-function studies for in vitro chemical inhibition of Fc gamma receptor-mediated phagocytosis. Transfusion 2007 47 : 290 8.
17. Bussel JB. Fc receptor blockade and immune thrombocytopenic purpura. Semin Hematol 2000 37 : 261 6.
18. Lazarus AH, Crow AR. Mechanism of action of IVIg and anti-D in ITP. Transfus Apher Sci 2003 28 : 249 55.
19. Shulman IA, Branch CA, Nitsun M, Gallagher MT, Branch DR. Thimerosal inhibition of monocyte-macrophage Fc-receptor (FcR) function. Blood 1986 68 (Suppl 1 86a.
20. Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980 26 : 171 6.
21. Branch DR, Gallagher MT, Mison AP, Sy Siok Hian AL, Petz LD. In vitro determination of red cell alloantibody significance using an assay of monocyte-macrophage interaction with sensitized erythrocytes. Br J Haematol 1984 56 : 19 29.
22. Auwerx J, Staels B, Van Vaeck F, Ceuppens JL. Changes in IgG Fc receptor expression induced by phorbol 12-myristate 13-acetate treatment of THP-1 monocytic leukemia cells. Leuk Res 1992 16 : 317 27.
23. Siegel J. Safety considerations in IGIV utilization. Int Immunopharmacol 2006 6 : 523 7.
24. Knezevic-Maramica I, Kruskall M. Intravenous immune globulins: an update for clinicians. Transfusion 2003 43 : 1460 72.
25. Ahaded A, Debbia M, Beolet M, LePennec PY, Lambin P. Evaluation by enzyme-linked immunosorbent assay of IgG anti-D and IgG subclass concentrations in immunoglobulin preparations. Transfusion 1999 39 : 515 21.
26. Golub ES. Immunology: a synthesis. Sunderland (MA) : Sinauer Associates 1987. p. 5 7.
27. Kumpel BM, Hadley AG. Functional interactions of red cells sensitized by IgG1 and IgG3 human monoclonal anti-D with enzyme-modified human monocytes and FcR-bearing cell lines. Mol Immunol 1990 27 : 247 56.
28. Song S, Crow AR, Siragam V, Freedman J, Lazarus AH. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. Blood 2005 105 : 1546 8.
29. Cooper N, Heddle NM, Haas M, Reid ME, Lesser ML, Fleit HB, Woloski BM, Bussel JB. Intravenous (IV) anti-D and IV immunoglobulin achieve acute platelet increases by different mechanisms: modulation of cytokine and platelet responses to IV anti-D by FcgammaRIIa and FcgammaRIIIa polymorphisms. Br J Haematol 2004 124 : 511 8.
30. Broussard LA, Hammett-Stabler CA, Winecker RE, Ropero-Miller JD. The toxicology of mercury. Lab Med 2002 33 : 614 25.
31. Bigham M, Copes R, Srour L. Exposure to thimerosal in vaccines used in Canadian infant immunization programs, with respect to risk of neurodevelopmental disorders. Can Commun Dis Rep 2002 28 : 69 80.
32. Doman C, Thorpe SJ, Thorpe R. Enhanced efficacy of anti-D immunoglobulin for treating ITP is not explained by higher immunoglobulin polymer content. Biologicals 2001 29 : 75 9.
33. Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002 107 : 387 93.
34. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005 310 : 1510 2.
35. Salama A, Kiefel V, Mueller-Eckhardt C. Effect of IgG anti-Rho(D) in adult patients with chronic autoimmune thrombocytopenia. Am J Hematol 1986 22 : 241 50.
36. Rossi E, Damasio EE, Cerri R, Sogno G, Lercari G, Incagliato M, Marmont A. Rhesus antibody treatment for idiopathic thrombocytopenic purpura in an Rh-negative patient. Haematologica 1988 73 : 521 3.
37. Song S, Crow AR, Freedman J, Lazarus AH. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIg. Blood 2003 101 : 3708 12.